{"title":"Minuteman Therapeutics","summary":"Minuteman Therapeutics is an early-stage company developing personalized oncolytic viruses, viruses designed to infect and break down cancer cells, matched to the biology of an individual patient's tumor.","body":"Minuteman Therapeutics is an early-stage company building personalized oncolytic viruses for cancer. Its site describes the goal as viruses matched to the biology of an individual patient's tumor. It is part of the Even One Ventures portfolio, a group of companies started to make scientific advances reach patients faster.\n\n## What it is working on\n\nOncolytic viruses are viruses designed to infect cancer cells, replicate inside them and break those cells down as they spread. Minuteman's site says that, in principle, they can do two things at once: attack the tumor directly and recruit the immune system against it.\n\nThe site notes that most viral therapies have been built as fixed products for broad groups of patients. Minuteman says it is taking a different path, with oncolytic virus approaches matched to one person's tumor.\n\n## Where it stands\n\nThis is early. As of October 24, 2026, the site does not list a clinical trial, a price, eligibility rules or a date when patients could receive a treatment. I would treat it as a company to follow and ask questions of, not a treatment you can sign up for today.\n\n## How to start\n\nThe site invites patients to email the company, and says it will be in touch. Bring a short summary of your diagnosis and treatment history if you reach out.\n\n## How it fits\n\nLike [Echo Immune](/companies/echo-immune/) and [Serova](/companies/serova/), Minuteman is working on a treatment built around one patient's tumor. Those two make personalized vaccines; Minuteman is working with viruses. If you are exploring options like these, [Clinical trials](/resources/clinical-trials/) and [Tumor testing](/resources/tumor-testing/) explain the groundwork that usually comes first, and [Personalized cancer vaccines: what to ask](/resources/cancer-vaccines/) has questions that apply to other personalized approaches too.\n\n## Questions I would ask\n\n1. Is anything open to patients now, such as a study or an expanded access path?\n2. What information about my tumor would you need, and would existing sequencing be enough?\n3. How would my oncologist be involved?\n4. What safety data exists so far for your approach?\n5. What would it cost, and who would pay?\n\n## Contacts\n\n- Website: [minuteman.bio](https://minuteman.bio/)\n- Email: [hello@minuteman.bio](mailto:hello@minuteman.bio)","topics":["emerging-research"],"capabilities":["emerging-research"],"organizationType":"company","services":["experimental-programs"],"communityFocus":["People with any type of cancer","Caregivers"],"sources":[{"id":"minuteman-home","label":"Minuteman Therapeutics: home page","url":"https://minuteman.bio/","publisher":"Minuteman Therapeutics","checkedAt":"2026-10-24","supports":"Personalized oncolytic virus approaches matched to the biology of an individual tumor; how oncolytic viruses work; contact by email.","type":"official"},{"id":"evenone-portfolio","label":"Even One Ventures: portfolio","url":"https://evenone.ventures/","publisher":"Even One Ventures","checkedAt":"2026-10-24","supports":"Minuteman Tx listed as an oncology company in the Even One Ventures portfolio.","type":"official"}],"applicability":"For patients and caregivers who want to follow or ask about personalized viral therapies for cancer. Inclusion is not a recommendation or a finding that this approach is right for your situation.","limitations":"Early stage. As of October 24, 2026, the company site does not describe a clinical trial, a price, eligibility or availability for patients. Details are as the company describes them. Talk with your oncologist before pursuing any experimental treatment.","disclosure":{"type":"none","text":"I have no financial or business relationship with Minuteman Therapeutics."},"reviewedAt":"2026-10-24","relatedIds":["9eec2ffb-1476-4c56-9915-51ec10135591","45dd3750-3fe0-4621-9723-fc49fdeaffc2","966ad3d5-e20a-40de-ba3d-cb072e57ebef","bcbf518f-872e-434c-b031-3d6c266ceaa4","f7221927-6b87-4be3-9a7c-906768a192a5"],"assetIds":["68a0d346-31c5-407a-b7dd-3b8b9e05655b","3c7142bd-fdfc-4595-a8ed-121ff961a829"],"logoAssetId":"68a0d346-31c5-407a-b7dd-3b8b9e05655b","logoBackground":"light","relatedX":[],"website":"https://minuteman.bio/","serviceStatus":"research","access":{"label":"Contact Minuteman by email","url":"https://minuteman.bio/"},"facts":[{"label":"Approach","value":"Personalized oncolytic viruses matched to the biology of an individual patient's tumor.","sourceIds":["minuteman-home"]},{"label":"Stage","value":"Early stage. The site lists no clinical trial, price or availability as of October 24, 2026.","sourceIds":["minuteman-home"]},{"label":"How to start","value":"Email the company through the contact on its site.","sourceIds":["minuteman-home"]},{"label":"Backer","value":"Part of the Even One Ventures portfolio.","sourceIds":["evenone-portfolio"]}],"id":"36997b0b-316e-4ca5-a3dd-9339aa2c60bb","kind":"company","slug":"minuteman-therapeutics","revision":"9269593c-7900-4046-99c2-c78bbf231ef3","canonicalUrl":"https://kevinwimer.com/companies/minuteman-therapeutics/","publishedAt":"2026-10-25T03:24:34.854Z","updatedAt":"2026-10-25T03:24:34.854Z","previewOnly":false,"shareImageAssetId":"3c7142bd-fdfc-4595-a8ed-121ff961a829"}